发明名称 |
Ointment with excellent formulation stability |
摘要 |
Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene·3/2 hydrate, 3 to 7% by weight of a separation inhibitor, 15 to 50% by weight of a hydrocarbon gel, a pH controller and 0.05 to 0.4% by weight of an antioxidant, has excellent drug stability and excellent drug dispersibility. In the present ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant. |
申请公布号 |
US9555025(B2) |
申请公布日期 |
2017.01.31 |
申请号 |
US201214008413 |
申请日期 |
2012.03.28 |
申请人 |
Maruho Co., Ltd.;Mitsubishi Tanabe Pharma Corporation |
发明人 |
Sakaguchi Tomoki;Emi Hidetoshi |
分类号 |
A61K31/4709;A61K9/00;A61K47/10;A61K47/12;A61K47/14;A61K47/18;A61K47/22 |
主分类号 |
A61K31/4709 |
代理机构 |
Muncy, Geissler, Olds & Lowe, P.C. |
代理人 |
Muncy, Geissler, Olds & Lowe, P.C. |
主权项 |
1. An ointment comprising:
(i) an oil phase containing: 3 to 7% by weight of a separation inhibitor selected from the group consisting of polyoxyethylene (196) polyoxypropylene (67) glycol, cetostearyl alcohol, behenyl alcohol, cetyl palmitate, polyoxyethylene (160) polyoxypropylene (30) glycol and polyoxyethylene (54) polyoxypropylene (39) glycol, and 15 to 50% by weight of a hydrocarbon gel, and (ii) a drug phase being a homogenous solution in which 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene×3/2hydrate, diisopropanolamine as a pH controller, and 0.05 to 0.4% by weight of an antioxidant selected from the group consisting of dibutylhydroxytoluene, butylhydroxyanisole, propyl gallate, tocopherol and pentaerythrityl-tetrakis[3-(3,5-di-t-butyl-4-hydroxyphenyl)propionate] are dissolved in an aqueous base, the pH of the drug phase being in the range of 8 to 10.5. |
地址 |
Osaka-shi, Osaka JP |